DYNAVAX TECHNOLOGIES news, videos and press releases - Page 3
For more news please use our advanced search feature.
DYNAVAX TECHNOLOGIES - More news...
DYNAVAX TECHNOLOGIES - More news...
- Dynavax Reports First Quarter 2022 Financial Results
- Dynavax to Report First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Financial Guidance
- Dynavax to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax Highlights 2022 Priorities and Announces Initiation of Phase 1 Clinical Trial for Its Shingles Vaccine Candidate
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
- COVID-19 Vaccine Developed by Biological E Using Dynavax's CpG 1018 Adjuvant Receives India DCGI Approval for Emergency Use
- Elaine D. Sun Appointed to Dynavax Board of Directors
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax to Present at the 4th Annual Evercore Virtual ISI HealthCONx Conference
- Dynavax Reports Third Quarter 2021 Financial Results
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Scott Myers Appointed to Dynavax Board of Directors and Elected Board Chairman
- Dynavax to Report Third Quarter 2021 Financial Results and Host Conference Call on November 4, 2021
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dynavax to Present at Upcoming Investment Conferences
-
“The Buzz'' Show: Dynavax Technologies Corp (NASDAQ: DVAX) Positive Clover Covid-19 Trial Data
- COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial
- Dynavax to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
- Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Thinking about buying stock in Skillz, Rigel Pharmaceuticals, Dynavax Technologies, Bellicum Pharmaceuticals, or Baudax Bio?
- Thinking about buying stock in PainReform, Gap, Multiplan, Aterian, or Dynavax Technologies?
- Medigen Vaccine Biologics Announces Launch of Its COVID-19 Vaccine MVC-COV1901 Adjuvanted with Dynavax's CpG 1018 Adjuvant
- Dynavax Announces Second Quarter 2021 Financial Results
